EDITRA MODERNA TRIAL

Federal officials told the committee that Moderna, Pfizer and other vaccine makers are not currently coordinating their clinical studies on redesigned shots, which could complicate the process of selecting the most effective vaccine for the fall. However, some FDA committee members were skeptical that new shots are needed right now, noting the current vaccines remain effective at preventing severe illness. has until June to decide whether new Covid shots that target mutations are needed ahead of an expected wave of infection in the fall. Peter Marks, told the agency's advisory committee earlier this month that the U.S. The Food and Drug Administration's top vaccine official, Dr. The company expects initial data on that shot in the second quarter of this year. CEO Stephane Bancel said that shot is the company's lead candidate for a fall booster in the Northern Hemisphere, which includes the U.S. Moderna is developing an additional vaccine that includes the Wuhan strain and 32 mutations present in the omicron Covid variant.

EDITRA MODERNA TRIAL

Most of the trial population was white, while 13% were Hispanic and 6% Black in the group that received the 50-microgram dose. The average age of the participants was about 50 years of age, 56% of whom were female. The clinical trial included 895 participants who received a single booster dose of the updated shot with either a 50-microgram or 100-microgram dosage.

The most common side effects of the updated 50-microgram shot were injection site and muscle pain, fatigue and headache, according to the data. The data has not undergone peer review by outside scientists.

The updated shot also increased antibody levels against the delta variant six months after injection, though they were lower than the response observed with omicron and did not show superior results in comparison to the original booster. Third shots of the current vaccine also boost protection against infection and hospitalization.ДЄ 50-microgram dose of Moderna's new vaccine doubled the antibodies, which block the virus from infecting human cells, against the omicron variant six months after injection compared with the original booster at the same dosage, the data indicated. Two doses of the original vaccines still provide strong protection against hospitalization, though effectiveness against severe illness also has dropped. But the more the spike protein has evolved, the less likely the antibodies produced by the vaccine are able to recognize the virus and fight it, which reduces the efficacy of the shots. The current vaccines were developed to recognize the spike protein, which the virus uses to invade human cells, of the Wuhan strain of Covid.

Editra moderna